Off-rate screening for selection of high-affinity anti-drug antibodies  by Ylera, Francisco et al.
Analytical Biochemistry 441 (2013) 208–213Contents lists available at ScienceDirect
Analytical Biochemistry
journal homepage: www.elsevier .com/locate /yabioOff-rate screening for selection of high-afﬁnity anti-drug antibodies0003-2697  2013 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.ab.2013.07.025
⇑ Corresponding author.
E-mail address: francisco.ylera@abdserotec.com (F. Ylera).
Open access under CC BY-NC-ND license. Francisco Ylera ⇑, Stefan Harth, Dirk Waldherr, Christian Frisch, Achim Knappik
Bio-Rad AbD Serotec GmbH, 82178 Puchheim, Germanya r t i c l e i n f o
Article history:
Received 22 May 2013
Received in revised form 18 July 2013
Accepted 19 July 2013







Trastuzumaba b s t r a c t
The rapidly increasing number of therapeutic antibodies in clinical development and on the market
requires corresponding detection reagents for monitoring the concentration of these drugs in patient
samples and as positive controls for measurement of anti-drug antibodies. Phage display of large recom-
binant antibody libraries has been shown to enable the rapid development of fully human anti-idiotypic
antibodies binding speciﬁcally to antibody drugs, since the in vitro panning approach allows for incorpo-
ration of suitable blockers to drive selection toward the paratope of the drug. A typical bottleneck in anti-
body generation projects is ranking of the many candidates obtained after panning on the basis of
antibody binding strength. Ideally, such method will work without prior labeling of antigens and with
crude bacterial lysates. We developed an off-rate screening method of crude Escherichia coli lysates con-
taining monovalent Fab fragments obtained after phage display of the HuCAL PLATINUM antibody
library. We used the antibody drugs trastuzumab and cetuximab as antigen examples. Using the Octet
RED384 label-free sensor instrument we show that antibody off rates can be reliably determined in crude
bacterial lysates with high throughput. We also demonstrate that the method can be applied to screening
for high-afﬁnity antibodies typically obtained after afﬁnity maturation.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. Advances in genetic engineering of antibodies [1] in combina-
tion with in vitro selection methods such as phage display [2–4]
have made it possible to create recombinant monoclonal antibod-
ies against virtually any target. Recombinant monoclonal antibod-
ies are identical to traditional monoclonal antibodies in their
functionality, but they offer greater ﬂexibility during their produc-
tion and more opportunities for optimization [5]. They have an
established track record in the development of human therapeutics
[2] and are increasingly being used for basic research [6–8].
The generation and optimization of monoclonal antibodies
using the HuCAL PLATINUM library [9] has been automated
[10]. In a typical selection experiment, after three consecutive
selection rounds on the antigen and subsequent cloning of the en-
riched antibody genes into an expression vector, transformed Esch-
erichia coli colonies are picked (typically 368 clones into one 384
microtiter plate) and screened for the presence of speciﬁc antibod-
ies using an indirect ELISA. Plasmids from several clones that con-
tain antigen-positive antibodies are isolated and sequenced to
identify unique antibody clones. These antibodies are then
expressed at a larger scale, puriﬁed, and further characterized [11].During thisprocess, theantibodydiversity obtained after panning
is reduced randomly at two steps: ﬁrst, the number of transformed
bacteria obtained after selection and subcloning results in typically
1000–10,000 colonies.Owing topractical considerations, only a frac-
tion (368 clones) is picked and further analyzed in the subsequent
ELISA (primary screening). Second, only a fraction of ELISA-positive
hits is then further characterized. Even thoughbinding to theantigen
canbe typically observed formore than20%of thepicked clonesdur-
ing the primary screening step, only about a third or less of these
clones are then sequenced, to keep the number of unique antibodies
for each antigen manageable during in-depth characterization. Pan-
ning using theHuCAL PLATINUM librarymay therefore result in sev-
eral hundredunique antibodies, but only a small fraction of these are
further analyzed. This fraction is selected based only on speciﬁc
binding in ELISA, not on other criteria such as binding strength.
The performance of an antibody in an assay often correlates
with its afﬁnity to the antigen, making it desirable to rank the anti-
bodies that are positive in the primary screening according to their
binding strength. Such a ranking step should ideally be integrated
into the automated processes and should be possible without prior
antibody puriﬁcation. We used the Octet RED384 instrument
(Pall ForteBio, Menlo Park, CA, USA) for developing a koff ranking
method, since it measures interaction kinetics by biolayer interfer-
ometry (BLI) and does not contain microﬂuidics, which might
interfere with using crude bacterial lysates. Crude E. coli lysates
are the simplest, fastest, and least expensive way to produce
antibodies and therefore most suitable for screening steps.
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bodies binding to therapeutic antibody drugs. Preclinical and clin-
ical development programs for therapeutic drugs require highly
speciﬁc detection reagents to measure their pharmacokinetics
(PK) in nonhuman and human subjects. PK analysis of human or
humanized antibody drugs requires idiotope-speciﬁc detection
reagents to achieve speciﬁc binding in the presence of a high con-
centration of human serum antibodies. Anti-idiotypic antibodies
that speciﬁcally bind to an antibody drug have been generated
by immunization [12,13] and, more recently, by phage display
[14,15].
Here we describe a high-throughput off-rate ranking process of
antibody Fab containing crude E. coli lysates using the Octet
RED384 instrument. The off rate was chosen as the ranking param-
eter because (i) the off rate is concentration-independent and can
therefore be applied to lysates in which the antibody concentration
is not known, (ii) antibody selection methods in phage display and
especially in afﬁnity-maturation projects are mostly off-rate based
[16], and (iii) a slow off rate is usually more important in assays
than a fast on rate, since a slow on rate can often be compensated
for with higher antibody concentration or longer incubation time,
whereas for an antibody with fast off rate the antibody is washed
off quickly.
This screening assay allows selection of clones with favorable
binding properties prior to further characterization and assay devel-
opment. We show that this method can be applied also to high-
afﬁnity antibodies obtained after an afﬁnity maturation project.Materials and methods
Antibody selection
Antibodies binding to cetuximab (Erbitux; Merck KGaA) were
selected from the HuCAL PLATINUM phage display library in three
rounds of selection on cetuximab immobilized on magnetic beads
(No. 14011; Life Technologies, Darmstadt, Germany) as described
by Jarutat et al. [11]. The library was blocked with 10% normal hu-
man serum (H4522; Sigma–Aldrich, Taufkirchen, Germany) and
50 lg/ml unrelated human antibody (No. I5154; Sigma–Aldrich)
and 50 lg/ml rituximab (in Europe, MabThera, Roche; in the
USA, Rituxan, Biogen Idec/Genentech). The selection output was
subcloned into the expression vector pMorph11_Fab-FH [9], which
leads to expression of monovalent antibody Fab fragments with a
FLAG and a His tag (Fab-FH format). After transformation of
E. coli TG1 and plating, 368 colonies were picked into a 384-well
microtiter plate with a MegaPix2 robot (Molecular Devices, Bibe-
rach an der Riss, Germany). A copy of this plate was used for Fab
expression. Crude bacterial lysates from the expression cultures
were prepared [11] and screened by ELISA on immobilized cetux-
imab, rituximab, and the unrelated human antibody used for
library blocking. Clones that bind cetuximab with a signal greater
than ﬁvefold over background and do not bind the control antibod-
ies were considered positive. From this primary screening all 83
positive clones were chosen for sequencing. The resulting unique
antibodies were expressed and puriﬁed by one-step afﬁnity chro-
matography via the His tag using a Ni-NTA matrix (Qiagen, Hilden,
Germany). Speciﬁcity of puriﬁed antibodies was conﬁrmed by indi-
rect ELISA on the antigen and on other proteins, including closely
related drug antibodies.Antibody afﬁnity optimization
HuCAL anti-trastuzumab antibodies were generated as de-
scribed for cetuximab. One of the resulting antibodies
(AbD16714, HCA167, Bio-Rad AbD Serotec, Oxford, UK) was subse-quently afﬁnity matured by exchange of the heavy chain CDR2
(HCDR2) with an HCDR2 library [5]. CDR exchange was done by
conventional restriction cloning making use of the modular design
of the HuCAL library [17]. High-diversity, high-quality CDR
libraries were generated through synthesis with trinucleotide
building blocks [9,18]. After generation of the corresponding anti-
body phage library three rounds of selection were performed un-
der more stringent conditions. Increased stringency was achieved
by antigen reduction and increased number of wash steps [5].
The following steps (subcloning, primary screening, expression,
and puriﬁcation) were performed as described above.
Off-rate screening
Off-rate screening and afﬁnity determination were performed
on an Octet RED384 instrument (Pall ForteBio). All measurements
were performed at 30C; 384-well microplates (No. 781209, Grein-
er Bio-One, Frickenhausen, Germany) were agitated at 1000 rpm.
Lysates of the 83 (cetuximab) or 95 (trastuzumab) selected positive
clones from the primary screening were transferred to a new 384-
well microtiter plate for secondary screening. Cetuximab (10 lg/
ml) in 10 mM sodium acetate, pH 5, was covalently immobilized
on amine-reactive second-generation sensors (AR2G; Pall ForteBio)
via EDC/NHS coupling chemistry for 10 min; excess reactive esters
were blocked with ethanolamine afterward. Trastuzumab (Hercep-
tin; Roche) was biotinylated using EZ-Link sulfo-NHS-LC-biotin
(Thermo Fisher Scientiﬁc, Bonn, Germany) according to the manu-
facturer’s protocol and immobilized at a concentration of 10 lg/ml
on streptavidin sensors (Pall ForteBio) for 10 min. Typical immobi-
lization levels were 4.5 ± 0.3 nm for cetuximab and 1.5 ± 0.1 nm for
trastuzumab. After loading, sensors were kept in phosphate-buf-
fered saline (PBS) until needed (for up to 1 day). For off-rate
screening, sensors were blocked with E. colimock lysate containing
no antibody for 5 min, transferred to the wells containing the anti-
body lysate for the association step (5 min), and transferred back to
the mock lysate for the measurement of the dissociation step
(5 min). Using new sensors for each sample, a total of 16 samples
were measured in parallel. Dissociation rate constants (koff) for
each antibody were calculated applying a 1:1 interaction model
(ﬁtting local, full) using the ForteBio data analysis software
7.0.1.5. Curves that could not be reliably ﬁtted with the software
(mostly full R2 < 0.96), usually caused by heterogeneous binding,
were excluded from further analysis.
Afﬁnity determination of puriﬁed Fab fragments
Kinetic constants were determined for each of the puriﬁed Fab
antibodies (molecular mass 52 kDa) at ﬁve concentrations between
2.5 and 0.16 lg/ml diluted in running buffer (PBS with 0.1% (w/v)
bovine serum albumin (BSA) and 0.02% (v/v) Tween 20). Cetux-
imab or trastuzumab was immobilized on the sensors under the
same conditions as described for the off-rate screening. Between
measurements the cetuximab biosensor surfaces were regenerated
twice by exposing them to 10 mM glycine, pH 2.0, for 10 s followed
by PBS for 30 s. For Herceptin; zumab, the same procedure using
10 mM glycine, pH 2.5, was applied. Association phase was mea-
sured for 300 s, dissociation phase depending on the interaction
for 300–1400 s. All measurements were corrected for baseline drift
by subtracting a control sensor exposed to running buffer only. Data
were analyzed using a 1:1 interactionmodel (ﬁtting global, Rmax un-
linked by sensor) on the ForteBio data analysis software 7.0.1.5.
Bridging ELISA
Matured and parental anti-trastuzumab antibodies were com-
pared as positive control standards in an anti-drug antibody
210 Off-rate screening for selection of high-afﬁnity anti-drug antibodies / F. Ylera et al. / Anal. Biochem. 441 (2013) 208–213bridging assay. Trastuzumab was coated on Maxisorp plates (Ther-
mo Fisher Scientiﬁc) at 0.5 lg/ml in PBS. After blocking with 5% (w/
v) BSA in PBS containing 0.05% (v/v) Tween 20 (PBST) for 1 h, the
anti-idiotypic antibodies (AbD16714_hIgG1 & AbD18018_hIgG1,
HCA177, Bio-Rad AbD Serotec) were added at concentrations from
8000 to 0.1 ng/ml in PBST with 10% normal human serum (Sigma;
H4522) and incubated for 1 h at room temperature. Detection was
performed with horseradish peroxidase-conjugated trastuzumab
(conjugated with a Lynx kit; Bio-Rad AbD Serotec) at 2 lg/ml in
HiSpec buffer (Bio-Rad AbD Serotec) followed by QuantaBlu ﬂuo-
rescence reagent (Thermo Fisher Scientiﬁc). Fluorescence signal
was read out on a Tecan Inﬁnite photometer (excitation 320 nm,
emission 430 nm).
Results
Anti-idiotypic antibodies were generated against the therapeu-
tic chimeric antibody cetuximab and the therapeutic humanized
antibody trastuzumab (both IgG1/j) using the HuCAL PLATINUM
library. During the selection procedure, isotype-matched blocking
antigens and human serum were added to remove binders that
were not drug-speciﬁc and bound to the constant Ig regions. After
selection, the enriched antibody genes were subcloned as a pool
into a vector for monovalent Fab expression. A monovalent format
was chosen to avoid avidity effects during the off-rate ranking and
afﬁnity determination as they would be observed with full IgG.
For cetuximab, primary screening of 368 expression lysates by
ELISA on immobilized cetuximab resulted in 83 positive clones.
Sequencing of these clones resulted in 53 unique antibody
sequences. All 53 antibodies were expressed and puriﬁed and their
afﬁnities and kinetic constants were determined on the Octet
RED384. An example of the obtained curves is shown in Fig. 1A.
Speciﬁcity of the antibodies to the therapeutic antibody but not
to other unrelated human IgG1/j antibodies was conﬁrmed by
ELISA (data not shown).
Similar to the anti-cetuximab antibodies, antibodies against
trastuzumab were generated (not shown). One of the resulting
anti-trastuzumab antibodies (clone AbD16714) was then afﬁnity
matured by inserting diversity into the heavy chain CDR2 region.
After three rounds of selection using this HCDR2-diversiﬁed matu-
ration library and increasing the stringency of selection, the output
was subcloned and tested in primary screening as described above.
The number of positive clones is usually higher for this type of
maturation project, since all antibodies in the library differ in
one CDR only and the selection therefore starts with a high number
of speciﬁc antibodies. Consequently, primary screening resulted in
313 anti-trastuzumab-speciﬁc antibodies. Sequencing of 95 posi-
tive clones resulted in 70 unique antibody sequences. The antibod-Fig.1. Examples of afﬁnity determination on the Octet RED384 instrument for (A) a
concentrations: 2.5 to 0.16 lg/ml, 1:2 dilution. Data are shown in blue, the correspondiies were expressed and puriﬁed and their afﬁnities and kinetic
constants were determined (example in Fig. 1B).
All 83 antibody-containing lysates for cetuximab and 95 lysates
with the highest signal in ELISA for trastuzumab were then ana-
lyzed on the Octet RED384 on immobilized antigen (secondary
screening). The sensorgrams of the evaluated samples are shown
in Fig. 2. The off rates were calculated from the dissociation part
of the curves using the ForteBio data analysis software.
The ELISA signal in screening of lysates is dependent upon the
antibody concentration, which can vary considerably and is
typically not known. The same antibody at different concentrations
will give different signals, or different antibodies with the same
signal can have off rates that vary by a factor of 10 or more. Hence
the signals obtained in the primary screening ELISA do not
necessarily correlate with the corresponding antibody afﬁnities
(Fig. 3A and C).
To conﬁrm the off-rate values measured in the lysates during
secondary screening, the values were compared with the off rates
determined from measurements of the puriﬁed antibodies. The
graphical comparisons in Fig. 3B (cetuximab) and 3D (trast-
uzumab) show a good correlation (cetuximab, R2 = 0.64; trast-
uzumab, R2 = 0.73) of the data obtained from ranking the lysates
with the results obtained with the corresponding puriﬁed
antibodies.
We then compared the off rates of antibodies selected by
highest signal in ELISA with those that were ranked in secondary
screening. From the 20 clones with the highest ELISA signal in
the anti-cetuximab project we obtained 9 unique antibodies after
sequencing, which gave an even distribution over the range of
measured off rates (not shown). In contrast, by sequencing the
20 clones with the lowest koff obtained from the secondary
koff-based screening against cetuximab, 8 unique antibodies were
identiﬁed that exhibit slow off rates (Fig. 4A). Importantly, the
clone with the best koff rate was identiﬁed by the koff ranking step,
but would not have been identiﬁed using only ELISA signal
strength as the selection criterion. For cetuximab, the 53 antibod-
ies identiﬁed had afﬁnities in the range of 0.5 to 174 nM. The 8
antibodies selected from the koff-based screening had afﬁnities in
the range of 0.5 to 47 nM. Therefore, the additional screening step
allowed the selection of antibodies with higher afﬁnities.
The afﬁnities measured in the anti-trastuzumab optimization
project range from 65 pM to 4 nM. Again we could identify the
antibodies with the lowest koff using the secondary screening step
(Fig. 4B), demonstrating that this method can be applied for anti-
bodies with subnanomolar afﬁnities that are typically obtained
from afﬁnity maturation projects. Here, a 38-fold afﬁnity improve-
ment (KD from 2.5 nM down to 65 pM) was achieved with one CDR
diversiﬁcation followed by three rounds of stringent selection.n anti-cetuximab antibody and (B) an anti-trastuzumab antibody. Fab antibody
ng ﬁts in red.




Fig.3. Correlation of (A and C) ELISA signal and (B and D) koff ranking using E. coli lysates with the koff values measured with puriﬁed Fab antibodies. (A) and (B) for cetuximab,
(C) and (D) for trastuzumab.
Fig.4. Off rates of all identiﬁed antibodies are arrayed for (A) cetuximab and (B) trastuzumab. The antibodies that resulted from the best 20 off-rate screening hits are shown
as red diamonds. The parental antibody used as starting sequence for anti-trastuzumab afﬁnity maturation is shown as a green triangle (B).
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ﬁed as the one with highest afﬁnity after maturation with its
parental counterpart using a bridging ELISA format that is oftenused to measure anti-drug antibodies. Fig. 5 demonstrates the
increase in sensitivity obtained with the afﬁnity-matured
antibody.
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These results demonstrate that it is possible to rank antibody-
containing crude bacterial lysates with a high throughput accord-
ing to their off rates, even with antibodies that show subnanomolar
afﬁnities to their targets, as often obtained from maturation
libraries. Antibody generation from libraries by in vitro methods
such as phage display can result in various antibody formats such
as Fab or scFv fragments, depending on the design of the library
and the ﬁnal expression vector used [4]. If a truly monovalent for-
mat such as Fab is used, a true afﬁnity-based ranking step can be
introduced that uses immobilized antigen, which is not possible
because of avidity effects when bivalent or multivalent formats
are used. If the antibody is monovalent the ranking can be
performed also with immobilized dimeric and oligomeric antigens
such as with immunoglobulins used here, since the interaction still
follows a 1:1 model. Bivalent antibody formats such as the minian-
tibody [19] or full-length IgG can be constructed by simple cloning
afterward.
Afﬁnity or off-rate ranking of antibodies is an important tool
during antibody generation and was established on several plat-
forms. An afﬁnity ranking by ELISA offers a good throughput with-
out the requirement for expensive instruments and sensors [20].
However, this method facilitates only a rough ranking and does
not provide afﬁnities or dissociation rate constants, and it may
not work reliably for antibodies with subnanomolar afﬁnities that
often result from afﬁnity maturation. Quantitative screenings are
possible by solution equilibrium titration with the MSD technology
[21]. Since a dilution series is required for each sample, the number
of wells per sample multiplies, which makes this method laborious
and relatively expensive. However, this method allows measure-
ments in solution and is well suited to very high afﬁnity antibodies
down to the subpicomolar range. Quantitative rankings by surface
plasmon resonance (SPR) were established on different instru-
ments by immobilization of the antigen or capturing the antibody
from periplasmic fractions [22,23], lysates, or culture supernatants
[24–28] or with puriﬁed antibodies [29]. Immobilization of the
antibodies by capture reagents can be used to measure monovalent
afﬁnities for both mono- and bivalent antibody formats as long as
the antigen is a monomer. For di- or oligomeric antigens such as
the antibody drugs used here, the antigen is immobilized and a
monovalent antibody format, i.e., Fab or scFv, is required. MostFig.5. Immunogenicity assay with anti-trastuzumab antibodies: squares, afﬁnity-
matured AbD18018 (KD = 65 pM), and circles, AbD16714 (KD = 2.5 nM) as the
parental antibody, both converted into IgG1 format.label-free detection technologies, including SPR instruments, work
with a microﬂuidic system, which runs the analyte or buffer over
the sensor chip on which the ligand was immobilized before. In
SPR, analyte binding and release are measured by a change in the
refractive index [30]. Using crude bacterial lysates on instruments
with microﬂuidics always bears the risk of clogging of microchan-
nels and ﬂow cells and requires high instrument maintenance.
Using periplasmic lysates rather than crude bacterial lysates
reduces the risk of clogging to some extent but requires additional
work steps in the lysate preparation.
In BLI, the ligand is immobilized on a sensor tip, which is dipped
into the solution with analyte or buffer. Upon analyte binding a
change in the interference pattern of light that reﬂects at the sur-
face of the sensor tip is measured [31]. Since the instrument does
not use any microﬂuidics, kinetic assays can also be performed in
crude bacterial lysates, as demonstrated here. Off rates measured
in lysates match well with those of puriﬁed antibodies. The assay
is robust and suitable for day-to-day use. Sensors are relatively
inexpensive, which makes it possible to work without sensor
regeneration. This is an advantage when working with labile anti-
gens and whenever no positive control antibody is available for
optimizing regeneration conditions. The instrument provided sufﬁ-
cient throughput owing to its 16 channels. In a typical screening
experiment, 96 samples are measured in less than 2 h, enabling
several projects per day to be performed.
The secondary screening step described here will help to iden-
tify high-afﬁnity antibodies early in the antibody selection process.
Using the selection of anti-drug antibodies as examples, we have
successfully demonstrated the method using antibodies from a
naïve synthetic library as well as from an afﬁnity maturation li-
brary that contained high-afﬁnity antibodies. Identifying the anti-
bodies with lowest dissociation rates will lead to more sensitive
assays, as shown here for an anti-idiotypic anti-trastuzumab
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